Virogin Biotech Canada
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Virogin Biotech Canada sits in the upper half of US sponsors by registered trial count (#4,885 of 15,742 sponsors by registered trial count).
Virogin Biotech Canada: 2 sponsored US clinical trials, 2 recruiting.
Virogin Biotech Canada sponsors 2 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Intrahepatic Cholangiocarcinoma, with 1 trials.
Mid-pack sponsor footprint
Virogin Biotech Canada is in the upper half of sponsors by trial count (#4,885 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.
Open and recent trials
2 total, page 1 of 1
An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma
NCT05223816
Phase I Study VG2025 as a Single Agent and in Combination Therapy With Nivolumab in Subjects With Advanced Malignant Solid Tumors
NCT05266612
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 1 |
Therapeutic Areas
What is open in the Virogin Biotech Canada pipeline
2 recruiting of 2 indexed (100% open).
Phase mix: 0 late (III/IV) vs 2 early (I/II) (early-phase heavy).
Top condition: Intrahepatic Cholangiocarcinoma (1 trial), 2 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Virogin Biotech Canada: open-pipeline peers nationwide
Peers matched on 2 registered trials and 100% open enrollment, not the therapeutic-area sidebar.
Virogin Biotech Canada sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 2 trials (± recruiting share)
- 1200 Pharma · 2 trials · 50% recruiting
- 1ST Biotherapeutics · 2 trials · 50% recruiting
- 3 Waves Wellness · 2 trials · 0% recruiting
- 3EO Health · 2 trials · 0% recruiting
Sponsors near 100% open enrollment (± trial volume)
- AAVantgarde Bio Srl · 100% recruiting · 2 trials
- Acorn Biolabs · 100% recruiting · 3 trials
- Acrivon Therapeutics · 100% recruiting · 2 trials
- ADARx Pharmaceuticals · 100% recruiting · 4 trials
Related
What to do with this Virogin Biotech Canada page
2 registered trials is a research-attention snapshot, not an endorsement of Virogin Biotech Canada or any single study.
- 2 of Virogin Biotech Canada's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Intrahepatic Cholangiocarcinoma is the condition Virogin Biotech Canada studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Intrahepatic Cholangiocarcinoma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Virogin Biotech Canada pipeline card: 2 registered trials from official public datasets.Report a data error.